A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors

NCT06717022 | Recruiting

• 1 other identifier: CHT102SIIT-01
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

Objectives of Study：In this study investigators plan to evaluate the safety and efficacy of MSLN-targeting Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) in the treatment of MSLN-positive advanced solid tumors.

Conditions

Mesothelin Positive Tumors

Keywords

CHT102, a U CAR-T therapy for MSLN-positive advanced solid tumors

Outcome Measures

Primary Outcomes (1)

• Dose Limiting Toxicities (DLTs) occurence

  Adverse events assessed according to NCI-CTCAE v5.0 criteria

  Baseline up to 28 days after U CAR-T infusion

Secondary Outcomes (2)

• Objective Response Rate

  At 4 weeks, and overall

• Progression-free survival

  Assessed up to 6 months

Study Arms (1)

CHT102 allogeneic CAR T cells

EXPERIMENTAL

In the dose escalation phase of this study, one alternative dose and 4 dose groups (calculated by the number of CAR-positive T cells) were planned, each treatment lasted 28 days, and UCAR-T cells were transfused three times, respectively on D1, D5, and D9. The single dose within the group was fixed, and the dose between the groups was escalating dose. Each infusion dose was 2.5×106/kg (optional), 5×106/kg, 1×107/kg, 2×107/kg, and 3×107/kg, with a dose error of 20% allowed.

Biological: CHT102 allogeneic CAR T cells

Interventions

CHT102 allogeneic CAR T cells BIOLOGICAL

CHT102 allogeneic CAR T cells

CHT102 allogeneic CAR T cells

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Ability to understand and sign a written informed consent document；
• Age ≥18 years old, male or female；
• Histopathological confirmed advanced or metastatic solid tumors failed to at least standard first-line therapy or initially diagnosed advanced solid tumors that have no National Comprehensive Cancer Network (NCCN ）guideline recommended standard first-line therapy；
• Histopathology or cytology (paraffin section or fresh biopsy tumor tissue specimen) diagnosed as advanced/metastatic solid tumor (positive tumor MSLN expression (tumor MSLN positive (IHC 2+) confirmed by histology or pathology));
• At least one measurable lesion at baseline per RECIST version 1.1；
• The expected survival time is more than 12 weeks;
• ECOG(American Eastern Oncology Consortium) 0-1 points;
• The function of important organs is basically normal;
• The investigator determines that the patient must have fully recovered from previous treatment toxicity to ≤ grade 1, except in the following cases: a. Hair loss; b. Pigmentation; c. Long-term toxicity caused by radiotherapy, which could not be recovered according to the investigators; d. Platinum induced grade 2 or lower neurotoxicity (CTCAE 5.0);
• Subjects agree to use reliable and effective contraceptive methods for contraception within
• months after signing the informed consent form to receiving CAR-T cell infusion (excluding rhythm contraception).

You may not qualify if:

• Received any experimental drug treatment or used experimental devices within 28 days;
• Received anti-tumor therapy such as chemotherapy and targeted therapy within 4 weeks;
• Received cell therapy products other than MSLN targets within 1 month;
• Patients who have previously received other cell therapy products should be tested for RCL(Replication Competent Retrovirus ) during the screening period if any test result is positive;
• Received chemotherapy other than lymphocyte clearance chemotherapy within 14 days prior to CHT102 infusion;
• Received systemic corticosteroid therapy at doses greater than 10 mg/day prednisone (or equivalent doses of other corticosteroids) within 2 weeks；
• Patients receiving oral or intravenous anticoagulant therapy within 7 days prior to CHT102 cell infusion;
• Prior organ allograft transplantations or allogeneic hematopoietic stem cell transplantation;
• Patients with immune deficiency or autoimmune diseases, or who require immunosuppressants;
• Vaccination within 14 days of study enrollment, or who required live vaccine immunization during the study period;
• Active/symptomatic central nervous system metastases or meningeal metastases at the time of screening; subjects with brain metastases who have been treated must be confirmed to have no imaging evidence of progression ≥ 4 weeks after the end of treatment before they can be enrolled;
• Serious or uncontrollable systemic disease or any unstable systemic disease, including but not limited to uncontrolled hypertension, uncontrolled hyperglycemia, liver and kidney insufficiency or metabolic disease, central nervous system disease, etc;
• Have any of the following heart conditions:
• New York Heart Association (NYHA) stage III or IV congestive heart failure;
• Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months before enrollment;

Sponsors & Collaborators

• Tianjin Medical University Cancer Institute and Hospital: lead
• Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.: collaborator

Study Sites (1)

Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, China

RECRUITING

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 21, 2024
• First Posted: December 4, 2024
• Study Start: May 6, 2024
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): May 1, 2039
• Last Updated: December 4, 2024

Record last verified: 2024-11

Locations

CN (1)